Cantor Fitzgerald Reaffirms Overweight Rating for Intellia Therapeutics (NASDAQ:NTLA)
Cantor Fitzgerald restated their overweight rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $65.00 target price on the stock. A number of other brokerages have also issued reports on NTLA. Wedbush reiterated a neutral rating and set a […]
More Stories
Third Coast Bancshares (NASDAQ:TCBX) Reaches New 52-Week High – Time to Buy?
Third Coast Bancshares, Inc. (NASDAQ:TCBX – Get Free Report)’s stock price reached a new 52-week high during trading on Monday...
First American Financial (NYSE:FAF) Reaches New 1-Year High – Time to Buy?
First American Financial Co. (NYSE:FAF – Get Free Report)’s stock price hit a new 52-week high on Monday . The...
National Bank of Canada (TSE:NA) Reaches New 52-Week High – Time to Buy?
National Bank of Canada (TSE:NA – Get Free Report)’s stock price reached a new 52-week high during trading on Monday...
Piper Sandler Companies (NYSE:PIPR) Hits New 1-Year High – Time to Buy?
Piper Sandler Companies (NYSE:PIPR – Get Free Report)’s share price hit a new 52-week high during trading on Monday ....
Qsemble Capital Management LP Purchases 2,956 Shares of Lockheed Martin Co. (NYSE:LMT)
Qsemble Capital Management LP boosted its holdings in Lockheed Martin Co. (NYSE:LMT – Free Report) by 64.8% during the 3rd...
Canton Hathaway LLC Purchases 500 Shares of Salesforce, Inc. (NYSE:CRM)
Canton Hathaway LLC increased its position in shares of Salesforce, Inc. (NYSE:CRM – Free Report) by 46.0% in the third...